December 20, 2016 07:20 AM EST
R&D

Ake­bia forges $1B US pact with Ot­su­ka on lead drug for CKD, shares spike

John Carroll

Editor & Founder

Ake­bia $AK­BA has struck a land­mark $1 bil­lion part­ner­ship with Ot­su­ka for its late-stage drug vadadu­s­tat, an oral treat­ment for ane­mia re­lat­ed to chron­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times